Octant Bio is a developer of synthetic technology used to improve health and treat disease.
Octant Bio has raised $80.0M in total funding. The most recent round was Series B. The last funding was announced in April 2022.
Octant Bio's investors include Andreessen Horowitz, Lux Capital, SV Angel, Gaingels, 8VC.
Octant Bio is headquartered in Los Angeles, United States.
Octant Bio is a developer of synthetic technology used to improve health and treat disease.
Octant Bio is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Octant Bio — Funding & Investors." VCBacked, April 21, 2022, https://www.vcbacked.co/company/octant-bio. Accessed July 19, 2026.
VCBacked. (2022). Octant Bio — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/octant-bio
{{cite web |title=Octant Bio — Funding & Investors |url=https://www.vcbacked.co/company/octant-bio |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated